Chicago, IL – According to filings with the U.S. Securities and Exchange Commission, Novian Health is raising $19,800,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Henry Appelbaum played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Novian Health
Novian Health is a late-stage development medical device company based in Chicago, with a subsidiary, Novian Health SAS, in France. Novian Health has developed Novilase, a minimally invasive alternative to lumpectomy for the treatment of breast tumors using Interstitial Laser Therapy (ILT). Novian Health has received a CE Mark for focal destruction of malignant and benign breast tumors, the first thermal ablation device to be approved for breast cancer. Novian Healths technology enables breast surgeons and radiologists to ablate tumors with image-guided laser therapy. Novilase offers significant advantages over surgery including fewer retreatments, quicker recovery, less pain and fatigue, minimal scarring, and only requires local anesthesia. Novian will conduct a multicenter pivotal trial to evaluate Novilase laser therapy as a treatment for early-stage breast cancer. U.S. market clearance for the focal destruction of malignant tumors will be sought. Novian will begin commercialization in Europe.

To learn more about Novian Health, visit http://novianhealth.com/

Contact:
Henry Appelbaum, President and Chief Executive Officer
312-266-7200
happelbaum@novianhealth.com
https://www.linkedin.com/in/chip-appelbaum-73ab74/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved